Silvia Marchianò

Silvia Marchianò

Auto-generated profile, based on publicly available information

Silvia Marchianò

Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, the United States of America; Center of Cardiovascular Biology, University of Washington, Seattle, WA 98109, the United States of America; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98109, the United States of America

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Atherosclerosis
Verified
Journal Article
Closed access
Nicola FerriNicola Ferri
Nicola Ferri
SMSilvia Marchianò
Silvia Marchianò
GTGianpaolo Tibolla
Gianpaolo Tibolla
RBRoberta Baetta
Roberta Baetta
ADAshish Dhyani
Ashish Dhyani
ACAlberto Corsini
Alberto Corsini

1 May 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
MRMassimiliano Ruscica
Massimiliano Ruscica
Nicola FerriNicola Ferri
Nicola Ferri
Federica FogacciFederica Fogacci
Federica Fogacci
MRMartina Rosticci
Martina Rosticci
MBMargherita Botta
Margherita Botta
SBStefano Bacchelli
Stefano Bacchelli
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) circulating levels are significantly associated with an increased risk of cardiovascular events. This study aimed to evaluate the relationship between circulating levels of PCSK 9 and arterial stiffness, an early instrumental biomarker of cardiovascular disease risk, in a large sample of overall healthy participants. Methods and Results: From the historical cohort of the Brisighella Heart Study, after exclusion of active smokers, participants in secondary prevention for cardiovascular disease, and patients in treatment with statins or vasodilating agents, we selected 227 premenopausal women and 193 age‐matched men and 460 postmenopausal women and 416 age‐matched men. In these participants, we evaluated the correlation between PCSK 9 plasma circulating levels and pulse wave velocity. Postmenopausal women showed higher PCSK 9 levels (309.9±84.1 ng/mL) compared with the other groups ( P <0.001). Older men had significant higher levels than younger men (283.2±75.6 versus 260.9±80.4 ng/mL; P =0.008). In the whole sample, pulse wave velocity was predicted mainly by age (B=0.116, 95% CI 0.96–0.127, P <0.001), PCSK 9 (B=0.014, 95% CI 0.011–0.016, P <0.001), and serum uric acid (B=0.313, 95% CI 0.024–0.391, P =0.026). Physical activity, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, and estimated glomerular filtration rate were not associated with pulse wave velocity ( P >0.05).By considering the subgroups described, age and PCSK 9 levels were mainly associated with pulse wave velocity, which also correlated with serum uric acid in postmenopausal women. Conclusions: In the Brisighella Heart Study cohort, circulating PCSK 9 is significantly related to arterial stiffness, independent of sex and menopausal status in women.

6 August 2019 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
SMSilvia Marchianò
Silvia Marchianò
ABAlessandro Bertero
Alessandro Bertero
CMCharles E. Murry
Charles E. Murry

22 December 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
LHLouisa Helms
Louisa Helms
SMSilvia Marchiano
Silvia Marchiano
ISIan B. Stanaway
Ian B. Stanaway
THTien-Ying Hsiang
Tien-Ying Hsiang
BJBenjamin A. Juliar
Benjamin A. Juliar
BFBenjamin S. Freedman
Benjamin S. Freedman
Kidneys are critical target organs of COVID-19, but susceptibility and responses to infection remain poorly understood. Here, we combine SARS-CoV-2 variants with genome-edited kidney organoids and clinical data to investigate tropism, mechanism, and therapeutics. SARS-CoV-2 specifically infects organoid proximal tubules among diverse cell types. Infections produce replicating virus, apoptosis, and disrupted cell morphology, features of which are revealed in the context of polycystic kidney disease. Cross-validation of gene expression patterns in organoids reflects proteomic signatures of COVID-19 in the urine of critically ill patients indicating interferon pathway upregulation. SARS-CoV-2 viral variants alpha, beta, gamma, kappa, and delta exhibit comparable levels of infection in organoids. Infection is ameliorated in ACE2–/– organoids and blocked via treatment with de novo–designed spike binder peptides. Collectively, these studies clarify the impact of kidney infection in COVID-19 as reflected in organoids and clinical populations, enabling assessment of viral fitness and emerging therapies.

1 May 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
FPFederica Porta
Federica Porta
Giorgio FacchettiGiorgio Facchetti
Giorgio Facchetti
Nicola FerriNicola Ferri
Nicola Ferri
Arianna GelainArianna Gelain
Arianna Gelain
FMFiorella Meneghetti
Fiorella Meneghetti
IRISABELLA RIMOLDI
ISABELLA RIMOLDI

1 March 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
IRISABELLA RIMOLDI
ISABELLA RIMOLDI
Giorgio FacchettiGiorgio Facchetti
Giorgio Facchetti
GLGiorgio Lucchini
Giorgio Lucchini
ECElisa Castiglioni
Elisa Castiglioni
SMSilvia Marchianò
Silvia Marchianò
Nicola FerriNicola Ferri
Nicola Ferri